Items where authors include "Vile, RG"

Article

Schuelke, MR, Gundelach, JH, Coffey, M et al. (7 more authors) (2022) Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. Neuro-Oncology Advances, 4 (1). pp. 1-10. ISSN 2632-2498

Samson, A orcid.org/0000-0002-3081-7850, West, EJ orcid.org/0000-0001-7449-120X, Carmichael, J et al. (27 more authors) (2022) Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. Cancer Immunology Research, 10 (6). pp. 745-756. ISSN 2326-6066

Kottke, T, Tonne, J, Evgin, L et al. (19 more authors) (2021) Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature Communications, 12 (1). 1930. ISSN 2041-1723

Driscoll, CB, Schuelke, MR, Kottke, T et al. (17 more authors) (2020) APOBEC3B-mediated Corruption of the Tumor Cell Immunopeptidome Induces Heteroclitic Neoepitopes for Cancer Immunotherapy. Nature Communications, 11. 790. ISSN 2041-1723

Schuelke, MR, Wongthida, P, Thompson, J et al. (8 more authors) (2019) Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity. Journal for ImmunoTherapy of Cancer, 7 (1). 188. ISSN 2051-1426

Jennings, VA, Scott, GB orcid.org/0000-0003-0021-9400, Rose, AMS et al. (13 more authors) (2019) Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Molecular Therapy, 27 (6). pp. 1139-1152. ISSN 1525-0016

Huff, AL, Wongthida, P, Kottke, T et al. (12 more authors) (2018) APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Molecular Therapy - Oncolytics, 11. pp. 1-13.

Berkeley, RA, Steele, LP, Mulder, AA et al. (8 more authors) (2018) Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy. Cancer Immunology Research, 6 (10). pp. 1161-1173. ISSN 2326-6066

Forbes, NS, Coffin, RS, Deng, L et al. (20 more authors) (2018) White paper on microbial anti-cancer therapy and prevention. Journal for ImmunoTherapy of Cancer, 6 (1). ARTN 78. ISSN 2051-1426

Samson, A orcid.org/0000-0002-3081-7850, Scott, KJ orcid.org/0000-0002-5790-9579, Taggart, D et al. (36 more authors) (2018) Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine, 10 (422). eaam7577. ISSN 1946-6234

Shim, KG, Zaidi, S, Thompson, J et al. (8 more authors) (2017) Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy. Molecular Therapy, 25 (4). pp. 962-975. ISSN 1525-0016

Jebar, AH, Errington-Mais, F, Vile, RG et al. (3 more authors) (2015) Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of General Virology, 96 (7). 1533 - 1550. ISSN 0022-1317

Kyula, JN, Khan, AA, Mansfield, D et al. (16 more authors) (2013) Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/E BRAF mutant melanoma depends on JNK and TNF-α signaling. Oncogene, 33 (13). 1700 - 1712. ISSN 0950-9232

Twigger, K, Roulstone, V, Kyula, J et al. (14 more authors) (2012) Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer, 12. 368. ISSN 1471-2407